City Center Advisors LLC Invests $222,000 in Aurinia Pharmaceuticals Inc $AUPH

Key Points

• City Center Advisors LLC has invested $222,000 in Aurinia Pharmaceuticals by acquiring 26,155 shares during the second quarter.
• Aurinia Pharmaceuticals reported earnings per share of $0.16 for the last quarter, slightly missing the consensus estimate of $0.17, but exceeding revenue expectations with $70.01 million reported.
• Insider transactions saw Director Kevin Tang purchasing 200,000 shares for approximately $2.336 million, increasing his ownership in the company.

City Center Advisors LLC acquired a new position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP during the second quarter, according to its most recent 13F filing with the SEC. The firm acquired 26,155 shares of the biotechnology company's stock, valued at approximately $222,000.

Other large investors also recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new position in shares of Aurinia Pharmaceuticals in the 4th quarter worth about $27,000. Vermillion & White Wealth Management Group LLC purchased a new position in shares of Aurinia Pharmaceuticals in the 4th quarter worth about $31,000. GAMMA Investing LLC raised its holdings in shares of Aurinia Pharmaceuticals by 56.1% in the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock worth $39,000 after purchasing an additional 1,744 shares during the period. MAI Capital Management purchased a new position in shares of Aurinia Pharmaceuticals in the 1st quarter worth about $39,000. Finally, USA Financial Formulas purchased a new position in shares of Aurinia Pharmaceuticals in the 1st quarter worth about $50,000. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Stock Performance

Shares of NASDAQ:AUPH opened at $12.74 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 5.23. Aurinia Pharmaceuticals Inc has a one year low of $6.55 and a one year high of $12.87. The business's 50-day simple moving average is $10.76 and its 200 day simple moving average is $8.98. The company has a market cap of $1.68 billion, a P/E ratio of 29.63 and a beta of 1.26.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.01). Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.The business had revenue of $70.01 million for the quarter, compared to analysts' expectations of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

Insider Transactions at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Kevin Tang acquired 200,000 shares of the company's stock in a transaction on Tuesday, August 5th. The shares were bought at an average cost of $11.68 per share, for a total transaction of $2,336,000.00. Following the acquisition, the director directly owned 11,329,500 shares of the company's stock, valued at $132,328,560. This trade represents a 1.80% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders purchased 1,300,000 shares of company stock worth $13,590,000. 12.20% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Royal Bank Of Canada raised their target price on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a report on Friday, August 1st. HC Wainwright reiterated a "buy" rating and set a $17.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $12.00.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.